Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 9/20 | 0.57 |
| ▸ | ADORA3 | P0DMS8 | 11/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.51 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.51 |
| ▸ | ADA | P00813 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15459915 | 0.87 | ADORA2A (0.60) | ADORA2AADORA3ADORA1ADORA2BADA | |
| SCHEMBL14583683 | 0.87 | ADORA2A (0.60) | ADORA2AADORA3ADORA1ADORA2BADA | |
| SCHEMBL13559229 | 0.87 | ADORA2A (0.60) | ADORA2AADORA3ADORA1ADORA2BADA | |
| 2'-B-Methyl-Guanosine SCHEMBL10819905 | 0.86 | ADORA2A (0.65) | ADORA2AADORA3ADORA1ADORA2BADA | |
| 2'-B-Methyl-Guanosine SCHEMBL21007207 | 0.86 | ADORA2A (0.65) | ADORA2AADORA3ADORA1ADORA2BADA | |
| 2'-B-Methyl-Guanosine SCHEMBL15187539 | 0.86 | ADORA2A (0.65) | ADORA2AADORA3ADORA1ADORA2BADA | |
| 2'-B-Methyl-Guanosine SCHEMBL12149502 | 0.86 | ADORA2A (0.65) | ADORA2AADORA3ADORA1ADORA2BADA | |
| 2'-B-Methyl-Guanosine SCHEMBL18537392 | 0.86 | ADORA2A (0.65) | ADORA2AADORA3ADORA1ADORA2BADA | |
| 2'-B-Methyl-Guanosine SCHEMBL14842089 | 0.86 | ADORA2A (0.65) | ADORA2AADORA3ADORA1ADORA2BADA | |
| 2'-B-Methyl-Guanosine SCHEMBL12758165 | 0.86 | ADORA2A (0.65) | ADORA2AADORA3ADORA1ADORA2BADA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109976-A1 | SYNTHETIC ENGINEERED RNA MOLECULES AND RELATED METHODS | RNAV8 BIO INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20240139345-A1 | NUCLEIC ACID VECTORS AND METHODS OF USE | ALDEVRON, LLC | 2024-05-02 | — | — | US | disclosed |
| WO-2023215516-A2 | ACETYLATED RIBONUCLEIC ACIDS AND USES THEREOF | HELIX NANOTECHNOLOGIES, INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| US-9770463-B2 | Delivery of RNA to different cell types | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2017-09-26 | — | — | US | disclosed |
| US-20130195968-A1 | VIRION-LIKE DELIVERY PARTICLES FOR SELF-REPLICATING RNA MOLECULES | NOVARTIS AG (CH) | 2013-08-01 | — | — | US | disclosed |
| US-20130177640-A1 | DELIVERY OF RNA TO DIFFERENT CELL TYPES | NOVARTIS AG (CH) | 2013-07-11 | — | — | US | disclosed |
| US-20030007961-A1 | Orthomolecular vitamin E derivatives | WILBURN MICHAEL D (US) | 2003-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109976-A1 | SYNTHETIC ENGINEERED RNA MOLECULES AND RELATED METHODS | UPF1, RNGTT, NSUN3 | ADORA2A 3110/4885ADORA3 3580/4885ADORA1 4503/4885 |
| US-20030007961-A1 | Orthomolecular vitamin E derivatives | RBP4, RBP1, VDR | ADORA2A 2315/4885ADORA3 1274/4885ADORA1 1280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.